Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
ClinicalTrials.gov · NCT05524311 · Registry updated: 2026-04-23
- Condition / research focus
- Juvenile Dermatomyositis
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Countries with listed sites
- France
- Registry dates and results
- Start: 2022-11-10. Completion: 2026-01-02 (may be estimated). No results posted in this registry response.
Products and interventions (7)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Baricitinib (drug)
- pharmacokinetics study (biological)
- dosage of cytokines (biological)
- transcriptomic analysis (biological)
- Parent version of the Child Health Questionnaire (CHQ) (behavioral)
- Childhood Health Assessment Questionnaire (behavioral)
- Pregnancy test (biological)
Where the study takes place — 13 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.